PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Name | Title | Since | Age |
|---|---|---|---|
| Brooke Story | Independent Non-Employee Chairman of the Board | 2025 | 55 |
| Dikla Czaczkes Akselbrad | CEO & Director | 2022 | 53 |
| Itzhak Krinsky | Independent Non-Employee Director | 2019 | 73 |
| Nir Dror | Independent Non-Employee Director | 2025 | 50 |
| Yechezkel Barenholz | Independent Non-Employee Director | 2008 | 84 |
| Yafit Stark | Clinical Development Strategy Advisor | 2008 | 71 |
| Noam Emanuel | Member of Scientific Advisory Board of Drug Delivery | 2024 | 67 |
| Moshe Salai | Member of Scientific Advisory Board | - | - |
| Erez Kachel | Member of Scientific Advisory Board | - | - |
| Hartzell V. Schaff | Member of Scientific Advisory Board | 2017 | - |
| Robert Benjamin Stein | Independent Non-Employee Director | 2020 | 75 |
| Frederick F. Lang | Member of Scientific Advisory Board | 2021 | - |
| Mitchel S. Berger | Member of Scientific Advisory Board | 2022 | 73 |
| Joseph BenAmram | Independent Non-Employee Director | 2023 | 61 |
| Raanan Berger | Member of Scientific Advisory Board of Oncology | 2024 | - |
| Yitzchak Jacobovitz | Independent Non-Employee Director | 2025 | 50 |